08 May 2021>: Review Articles
A Review of Recent Research on the Role of MicroRNAs in Renal Cancer
Longfei Yang 1ABCDE , Xiaofeng Zou 2G , Junrong Zou 3D , Guoxi Zhang 2FG*DOI: 10.12659/MSM.930639
Med Sci Monit 2021; 27:e930639
Table 1 miRNAs act as tumor suppressors in renal cancer. A summary of miRNAs name, specimen types, targeted messenger RNAs, functions, and clinical application is provided.
MicroRNA | Specimen | Biological function | Clinical application | Target | Pathways | Ref. |
---|---|---|---|---|---|---|
miR-122-5p and miR-206 | In serum | liquid biopsy | []3 | |||
miR-144-5p | In vitro | Suppress cell proliferation, migration and invasion | DFS | SDC3 | []12 | |
miR-384 | In vitro | Inhibit cell proliferation, colony formation and invasion | AEG-1 | RAS signaling pathway | []14 | |
miR-106a-5p | In vitro and in vivo | Inhibit tumor metastasis | Diagnosis, potential therapeutic target | PAK5 | RAS signaling pathway | []15 |
miR-532-5p | In vitro and in vivo | Inhibit tumor growth and decrease expression of KRAS, NAP1L1, P-ERK and ETS1 | KRAS, NAP1L1 and ETS1 | MAPK signaling pathway | []16 | |
miR-199a | In vitro | Suppress cell proliferation, migration and invasion | ROCK1 | RAS signaling pathway | []17 | |
miR-622 | In vitro | Suppress cell migration and invasion and decrease levels of P-ERK | CCL18 | MAPK signaling pathway | []18 | |
miR-200b | In vitro and in vivo | Inhibit tumor metastasis and decrease levels of P-ERK | LAMA4 | MAPK signaling pathway | []19 | |
miR-363 | In vitro and in vivo | Suppress cell proliferation, migration and invasion, decrease level of STAT3, JAK2, VEGF, p-STAT3/JAK2/ERK, PDGF-A/B, N-cadherin, vimentin and ZEB1 | GHR, S1PR1 | MAPK/VEGF signaling pathway | [, ]20 | |
miR-10a-5p | In vitro | Suppresses cell proliferation, migration and invasion, reduce p-ERK1/2, AKT, FAK and SRC | Potential therapeutic target | SKA1 | MAPK and AKT signaling pathway | []21 |
miR-149 | In vitro | Inhibit cell migration, invasion and proliferation | FOXM1 | PI3K/AKT signaling pathway | []23 | |
miR-320a | In vitro and in vivo | Reduce tumor growth | OS, diagnosis | FoxM1 | PI3K/AKT signaling pathway | []24 |
miR-338-3p | In vitro | Increase cell proliferation and invasion | p-AKT and PI3K | PI3K/AKT signaling pathway | []25 | |
miR-15a | In vitro | Inhibit cell proliferation, invasion and induce apoptosis, decrease expression of P13K, p-AKT, mTOR, cyclin D1, cyclin E, Bax, c-Myc and MMP3 | eIF4E | P13K/AKT/mTOR signaling pathway | []26 | |
miR-488 | In vitro and in vivo | Reduce tumor growth and decrease expression of N-cadherin, vimentin, p-AKT, p-mTOR, and P13K | Potential therapeutic target | HMGN5 | P13K/AKT/mTOR signaling pathway | []27 |
miR-520c-3p/ 372-3p/373-3p | In vitro and in vivo | Decrease tumor growth, metastasis and increase the expression of E-cadherin and PTEN | SPOP | PI3K/AKT signaling pathway | []28 | |
miR-203 | In vitro and in vivo | Decrease tumor growth, metastasis and increase the expression of E-cadherin, PTEN, p21 and p27 | PI3K/AKT signaling pathway | []29 | ||
miR-148a | In vitro and in vivo | Reduce tumor growth and decrease p-Akt/mTOR, improve sensitivity to TRAIL and cisplatin | Potential therapeutic target | AKT2 and Rab14 | AKT signaling pathway | [, ]30 |
miR-766-3p | In vitro and in vivo | Reduce tumor growth and decrease P-AKT and P-ERK | OS | SF2 | AKT and MAPK signaling pathway | []32 |
miR-375 | In vitro | Inhibits cell proliferation, migration and invasion, while induce cell apoptosis | PDK1 | []33 | ||
miR-100 | In vitro | Inhibit cell invasion, migration and increase autophagy, reduce expression of mTOR, MMP-2 and MMP-9, whereas improve level of LC3 and LC3-II/LC3-I | NOX4 | mTOR signaling pathway | []34 | |
miR-205-5p | In vitro and in vivo | Repress tumor growth, inhibit expression of p-PI3K/Akt/-mTOR, increase sensitivity of cell to sunitinib, paclitaxel, 5-FU and oxaliplatin | OS, potential therapeutic target | VEGFA | VEGFA and Pl3k/AKT signaling pathway | []36 |
miR-299 | In vitro and in vivo | Suppress tumor growth and inhibit expression of vimentin and N-cadherin | VEGF | VEGF signaling pathway | []37 | |
miR-218 | In vitro and in vivo | Decreases the expression of VEGFA, p-PI3K/p-Akt/p-mTOR diminish tumor angiogenesis | OS | GAB2 | VEGFA and Pl3k/AKT/mTOR signaling pathway | []39 |
miR-125a-3p | In vitro | Inhibit the expression of VEGF and tube numbers formed by HUVECs | OS, DFS | VEGF | VEGF signaling pathway | []122 |
miR-148b-3p | in vitro and in vivo | Suppress tumor growth, tube formation of HUVECs and inhibit expression of HIF-1a, VEGF-A, PDGF-BB, and PDGF-D | FGF2 | VEGF signaling pathway | []41 | |
miR-486-5p | in vitro | Inhibit cell proliferation and induce apoptosis, decrease apoptosis resistance induced by CCL2 | TAK1 | TGF-β signaling pathway | []43 | |
miR-328 | In vitro | Inhibit cell proliferation | ITGA5 | TGF-β signaling pathway | []44 | |
miR-186 | In vitro | Inhibit cell proliferation, invasion and induce apoptosis, decrease level of p-IkBa and p-p65 | SENP1 | NF-κB signaling pathway | []46 | |
miR-765 | In vitro | Suppress tumor growth and inhibit expression of VEGFA and Ki67 and eliminate lipids accumulation | PLP2 | Metabolic related mechanism | []48 | |
miR-409-3p | In vitro | Decrease cell extracellular acidification rate, ATP production and increased oxygen consumption rate | PDK1 | Metabolic related mechanism | []50 | |
miR-497-5p | In vitro | Inhibit cell proliferation, migration and increase apoptosis | OS | PD-L1 | Immunity related mechanism | []51 |
miR-216a | In vitro and in vivo | Reduce tumor growth | TLR4 | Immunity related mechanism | []52 | |
miR-211-5p | In vitro and in vivo | Decrease tumor growth and metastasis | DFS, potential therapeutic target | SNAI1 | EMT program | []58 |
miR-124/203 | In vitro | Inhibit cell proliferation and migration | ZEB2 | EMT program | []59 | |
miR-101-5p | In vitro | Inhibit cell proliferation, invasion and induce apoptosis | slug | EMT program | []60 | |
miR-490-3p | In vitro and in vivo | Inhibit tumor growth and metastasis, decrease VM formation | TR4 | []61 | ||
miR-32-5p | In vitro and in vivo | Inhibit tumor metastasis and repress expression of TR4, HGF and p-Met | TR4 | []62 | ||
miR-451a | In vitro | Suppresses cell migration and invasion | PMM2 | []121 | ||
miR-200a-3p | In vitro and in vivo | Suppress tumor growth | CBL | []54 | ||
miR-182-5p | In vitro and in vivo | Inhibit tumor growth and metastasis, increase expression of P53 | []56 | |||
miR-376b-3p | In rcc tissues | PFS, diagnosis | []101 | |||
miR-9-5p | In rcc tissues | Diagnosis | []102 | |||
miR-10a-5p/ 10b-5p/106a-5p/142-5p | In rcc tissues | Diagnosis | []107 | |||
miR-1208 | In vitro | Inhibits cell proliferation and promote apoptosis, sensitizes cisplatin-induced apoptosis and TRAIL-induced apoptosis | Potential therapeutic target | TBCK | []111 | |
miR-99a-3p | In vitro | Inhibit cell proliferation and facilitate apoptosis, induce S phase arrest and increase sunitinib sensitivity | Potential therapeutic target | RRM2 | []112 | |
miR-126 | In vitro | Decrease cell migration and lactate production, inhibit expression of p-mTOR, and sensitize the cancer cells tocisplatin or X-ray treatment | Potential therapeutic target | SERPINE1 | mTOR signaling pathway | []113 |
miR-378a-5p | In vitro | Inhibit cell proliferation, migration, invasion and promote apoptosis | OS | []119 | ||
miR-31-5p | In vitro | Suppress cell proliferation, migration and invasion | OS | CDK1 | []120 | |
miR-22/24/99a/ 194/214/ 335/339/708 | Biomarker | []6 | ||||
miRNAs – microRNAs; DFS – disease-free survival; SDC3 – syndecan-3; AEG – 1-astrocyte-elevated gene-1; RAS – rat sarcoma; PAK5 – p21-activated kinase 5; KRAS – Kirsten rat sarcoma viral oncogene; p-ERK – phosphorylate extracellular signal regulated kinase; ETS1 – E26 transformation-specific-1; MAPK – mitogen-activated protein kinases; ROCK1 – Rho-associated coiled-coil-forming protein kinase 1; CCL18/2 – C-C motif chemokine 18/2; LAMA4 – laminin subunit alpha-4; STAT3 – signal transducer and activator of transcription 3; JAK2 – Janus kinases 2; VEGF – vascular endothelial growth factor; PDGF – platelet-derived growth factor; ZEB1 – zinc finger E-box binding homeobox 1; GHR – growth hormone receptor; S1PR1 – sphingosine-1-phosphate receptor 1; AKT – protein kinase B; FAK – focal adhesion kinase; SKA1 – spindle and kinetochore-associated protein 1; FOXM1 – forkhead box M1; OS – overall survival; PI3K – phosphatidylinositol 3-kinase; mTOR – mammalian target of rapamycin; MMP3 – matrix metalloproteinase-3; eIF4E – eukaryotic initiation factor 4E; HMGN5 – high-mobility group nucleosome binding domain 5; PTEN – phosphatase and tensin homolog deleted on chromosome 10; SPOP – speckle-type POZ protein; TRAIL – tumor necrosis factor-related apoptosis inducing ligand; Rab14 – ras-related protein 14; SF2 – splicing factor 2; PDK1 – phosphoinositide-dependent kinase 1; NOX4 – NADPH oxidase 4; LC3 – microtubule-associated protein 1 light chain 3; GAB2 – GRB2-associated binding protein 2; HUVECs – human umbilical vein endothelial cells; FGF2 – fibroblast growth factor 2; TAK1 – TGF-beta-activated kinase 1; ITGA5 – integrin alpha5; SENP1 – sentrin specific peptidase1; PLP2 – proteolipid protein 2; PD-L1 – programmed death ligand 1; TLR4 – toll-like receptor 4; SNAI1 – snail family transcriptional repressor 1; TR4 – testicular nuclear receptor 4; VM – vasculogenic mimicry; HGF – hepatocyte growth factor; PMM2 – phosphomannomutase 2; CBL – casitas B-lineage lymphoma; PFS – progression-free survival; TBCK – TBC1-domain-containing kinase; RRM2 – ribonucleotide reductase regulatory subunit m2; SLC7A5 – solute carrier family 7 member 5; HIF1a/2a – hypoxia inducible factor 1a/2a; SERPINE1 – serine protease inhibitor clade E member 1. |